Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial

Table 5 Mean difference of Anxiety and Depression scores in both placebo and bupropion group

(A)	(B)		Mean difference (A-B)	SE	95% Confidence interval of difference		P-value
					Lower	Upper
Baseline (HADS_A)	End of 2nd week (HADSA)	Placebo	0.37	0.28	- 0.26	0.98	0.2
	End of 2nd week (HADSA)	Bupropion	1	0.3	0.3	1.7	0.009
	End of 6th week (HADSA)	Placebo	2.07	0.67	0.6	3.5	0.009
	End of 6th week (HADSA)	Bupropion	3.6	0.5	2.5	4.7	0.001>
End of 2nd week (HADSA)	End of 6th week (HADSA)	Placebo	1.7	0.6	0.4	3	0.014
End of 2nd week (HADSA)	End of 6th week (HADSA)	Bupropion	2.6	0.4	1.7	3.48	0.001>
Baseline (HADSD)	End of 2nd week (HADSD)	Placebo	0.57	0.29	- 0.05	1.2	0.07
	End of 2nd week (HADSD)	Bupropion	1	0.25	0.4	1.5	0.002
	End of 6th week (HADSD)	Placebo	2.2	0.42	1.3	3.1	0.001>
	End of 6th week (HADSD)	Bupropion	2.9	0.4	2	3.8	0.001>
End of 2nd week (HADSD)	End of 6th week (HADSD)	Placebo	1.64	0.4	0.7	2.5	0.002
End of 2nd week (HADSD)	End of 6th week (HADSD)	Bupropion	1.9	0.38	1	2.7	0.001>

ISSN: 1471-2407